On August 19, 2026, the medical world took a massive leap forward. The FDA officially granted De Novo authorization to Aletta, a groundbreaking medical innovation developed by Vitestro. For the first time, a standalone robotic device is legally authorized to draw blood from an adult patient's arm autonomously, without any hands-on intervention from a human operator. Designed specifically for outpatient settings, this clearance creates an entirely new regulatory category for robotic phlebotomy.
While the idea of a robot drawing your blood might sound like science fiction, Aletta is designed to be gentle, precise, and completely independent.
Beyond the incredible technology, Aletta was built to solve a very real, human problem: the nationwide phlebotomist shortage. Because the robot handles the physical blood draw, a single trained phlebotomy supervisor can simultaneously oversee up to three Aletta devices at once. This drastically increases clinic efficiency and reduces wait times.
Getting blood drawn is rarely an enjoyable task, but Aletta’s consistency aims to change that. By removing the variability of human error, the device promises a highly predictable, standardized experience that may finally put needle-phobic patients at ease.
| Feature | Traditional Blood Draw | Aletta Robotic Draw |
| Operator | Hands-on Phlebotomist | Autonomous Device |
| Vein Detection | Visual and Tactile | Near-Infrared & Ultrasound |
| Oversight | 1:1 (Staff to Patient) | 1:3 (Staff to Devices) |